Skip to main content

Advertisement

SpringerLink
Log in

Invasive aspergillosis: an important risk factor on the short- and long-term survival of acute myeloid leukemia (AML) patients

  • Article
  • Published:
European Journal of Clinical Microbiology & Infectious Diseases Aims and scope Submit manuscript

Abstract

Invasive aspergillosis (IA) during induction chemotherapy of acute myeloid leukemia (AML) could worsen the prognosis. Our objective was to study how the development of IA during AML interferes with the therapeutic strategy and to evaluate its impact on the short- and long-term survival. Newly diagnosed AML patients between the years 2004 and 2007 were retrospectively analyzed. The outcome was death of the patient. A Cox proportional hazards model with the diagnosis of IA and post-induction response evaluation as the main exposure was fitted. Overall, 262 patients were analyzed and 58 IA were observed. The 2-year survival of patients having had remission of AML was 54% and, for patients with failure of chemotherapy, it was 5% (p < 0.001). The 2-year survival of patients having had IA was 14%, and without IA, it was 32% (p = 0.01). Multivariate analysis showed that IA was associated with a higher risk of death in case of remission compared to no IA (hazard ratio [HR] = 1.66 [1.05–2.65], p = 0.031) and also in case of failure (HR = 6.43, p < 0.001). IA was associated with an increased risk of death for patients if they were either in remission or in failure after induction chemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Michallet M, Ito JI (2009) Approaches to the management of invasive fungal infections in hematologic malignancy and hematopoietic cell transplantation. J Clin Oncol 27(20):3398–3409

    Article  PubMed  Google Scholar 

  2. Lin SJ, Schranz J, Teutsch SM (2001) Aspergillosis case–fatality rate: systematic review of the literature. Clin Infect Dis 32(3):358–366

    Article  PubMed  CAS  Google Scholar 

  3. Mahfouz T, Anaissie E (2003) Prevention of fungal infections in the immunocompromised host. Curr Opin Investig Drugs 4(8):974–990

    PubMed  CAS  Google Scholar 

  4. Herbrecht R, Natarajan-Amé S, Letscher-Bru V, Canuet M (2004) Invasive pulmonary aspergillosis. Semin Respir Crit Care Med 25(2):191–202

    Article  PubMed  Google Scholar 

  5. Yeghen T, Kibbler CC, Prentice HG, Berger LA, Wallesby RK, McWhinney PH, Lampe FC, Gillespie S (2000) Management of invasive pulmonary aspergillosis in hematology patients: a review of 87 consecutive cases at a single institution. Clin Infect Dis 31(4):859–868

    Article  PubMed  CAS  Google Scholar 

  6. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL, Young LS (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34(6):730–751

    Article  PubMed  Google Scholar 

  7. Maertens J, Theunissen K, Verhoef G, Verschakelen J, Lagrou K, Verbeken E, Wilmer A, Verhaegen J, Boogaerts M, Van Eldere J (2005) Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 41(9):1242–1250

    Article  PubMed  CAS  Google Scholar 

  8. Martino R, Viscoli C (2006) Empirical antifungal therapy in patients with neutropenia and persistent or recurrent fever of unknown origin. Br J Haematol 132(2):138–154

    Article  PubMed  CAS  Google Scholar 

  9. Prentice HG, Kibbler CC, Prentice AG (2000) Towards a targeted, risk-based, antifungal strategy in neutropenic patients. Br J Haematol 110(2):273–284

    Article  PubMed  CAS  Google Scholar 

  10. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, Helfgott D, Holowiecki J, Stockelberg D, Goh YT, Petrini M, Hardalo C, Suresh R, Angulo-Gonzalez D (2007) Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356(4):348–359

    Article  PubMed  CAS  Google Scholar 

  11. Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, Greinix H, Morais de Azevedo W, Reddy V, Boparai N, Pedicone L, Patino H, Durrant S (2007) Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 356(4):335–347

    Article  PubMed  CAS  Google Scholar 

  12. De Pauw BE, Donnelly JP (2007) Prophylaxis and aspergillosis—has the principle been proven? N Engl J Med 356(4):409–411

    Article  PubMed  Google Scholar 

  13. Pagano L, Caira M, Candoni A, Offidani M, Martino B, Specchia G, Pastore D, Stanzani M, Cattaneo C, Fanci R, Caramatti C, Rossini F, Luppi M, Potenza L, Ferrara F, Mitra ME, Fadda RM, Invernizzi R, Aloisi T, Picardi M, Bonini A, Vacca A, Chierichini A, Melillo L, de Waure C, Fianchi L, Riva M, Leone G, Aversa F, Nosari A (2010) Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. Haematologica 95(4):644–650

    Article  PubMed  Google Scholar 

  14. Michallet M, Sobh M, Morisset S, Kraghel S, Nicolini FE, Thomas X, Bienvenu AL, Picot S, Nicolle MC, Vanhems P (2011) Risk factors for invasive aspergillosis in acute myeloid leukemia patients prophylactically treated with posaconazole. Med Mycol (in press)

  15. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van Burik JA, Wingard JR, Patterson TF; Infectious Diseases Society of America (2008) Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 46(3):327–360

    Article  PubMed  CAS  Google Scholar 

  16. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A, Goldstone A (1998) The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children’s Leukaemia Working Parties. Blood 92(7):2322–2333

    PubMed  CAS  Google Scholar 

  17. Byrd JC, Mrózek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, Pettenati MJ, Patil SR, Rao KW, Watson MS, Koduru PR, Moore JO, Stone RM, Mayer RJ, Feldman EJ, Davey FR, Schiffer CA, Larson RA, Bloomfield CD; Cancer and Leukemia Group B (CALGB 8461) (2002) Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 100(13):4325–4336

    Article  PubMed  CAS  Google Scholar 

  18. Cheson BD, Cassileth PA, Head DR, Schiffer CA, Bennett JM, Bloomfield CD, Brunning R, Gale RP, Grever MR, Keating MJ (1990) Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 8(5):813–819

    PubMed  CAS  Google Scholar 

  19. Herbrecht R, Letscher-Bru V, Oprea C, Lioure B, Waller J, Campos F, Villard O, Liu KL, Natarajan-Amé S, Lutz P, Dufour P, Bergerat JP, Candolfi E (2002) Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol 20(7):1898–1906

    Article  PubMed  Google Scholar 

  20. Marr KA, Balajee SA, McLaughlin L, Tabouret M, Bentsen C, Walsh TJ (2004) Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis 190(3):641–649

    Article  PubMed  CAS  Google Scholar 

  21. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW, Patterson TF, Maschmeyer G, Bille J, Dismukes WE, Herbrecht R, Hope WW, Kibbler CC, Kullberg BJ, Marr KA, Muñoz P, Odds FC, Perfect JR, Restrepo A, Ruhnke M, Segal BH, Sobel JD, Sorrell TC, Viscoli C, Wingard JR, Zaoutis T, Bennett JE; European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group (2008) Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 46(12):1813–1821

    Article  PubMed  Google Scholar 

  22. Maertens J, Frère P, Lass-Flörl C, Heinz W, Cornely O (2010) Antifungal prophylaxis in leukemia patients: 2009 update of the ECIL-1 and 2 guidelines. LeukemiaNet Web site. Available online at: http://www.eortc.org/home/IDG/ECIL/ECIL3_Antifungal_prophylaxis_update_2009.pdf

  23. National Comprehensive Cancer Network (NCCN) (2009) NCCN clinical practice guidelines in oncology: prevention and treatment of cancer-related infections. V.2.2009. NCCN web site. Home page at: http://www.nccn.org

  24. Pagano L, Caira M, Offidani M, Martino B, Candoni A, Valentini CG, Specchia G, Nosari A, Tosti ME, Leone G, Luppi M, Aversa F (2010) Adherence to international guidelines for the treatment of invasive aspergillosis in acute myeloid leukaemia: feasibility and utility (SEIFEM-2008B study). J Antimicrob Chemother 65(9):2013–2018

    Article  PubMed  CAS  Google Scholar 

  25. Garfield FB, Garfield JM (2000) Clinical judgment and clinical practice guidelines. Int J Technol Assess Health Care 16(4):1050–1060

    Article  PubMed  CAS  Google Scholar 

  26. Leventakos K, Lewis RE, Kontoyiannis DP (2010) Fungal infections in leukemia patients: how do we prevent and treat them? Clin Infect Dis 50(3):405–415

    Article  PubMed  Google Scholar 

  27. Sá MB, Zaragoza R (2008) Critical overview of clinical guidelines relating to invasive fungal infections. Int J Antimicrob Agents 32(Suppl 2):S155–S159

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

No conflict of interest to declare.

Author information

Authors and Affiliations

  1. Hematology Department, Edouard Herriot Hospital, Hospices Civils de Lyon, 5 Place d’Arsonval, 69437, Lyon Cedex 03, France

    M. Michallet, M. Sobh, S. Kraghel, M. El Hamri, G. Cannas, F. E. Nicolini, H. Labussière, S. Ducastelle, F. Barraco, X. Thomas & Y. Chelghoum

  2. Laboratoire d’Epidémiologie et de Santé Publique, CNRS, UMR 5558, Université Lyon 1, Lyon, France

    T. Bénet & P. Vanhems

  3. Département d’Hygiène, Epidémiologie et Prévention, Edouard Herriot Hospital, Lyon, France

    M.-C. Nicolle & P. Vanhems

  4. Service Paludisme, Parasites du Sang et Mycologie Médicale, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, 103 Grande rue de la Croix-Rousse, 69317, Lyon, France

    A.-L. Bienvenu, F. Persat, F. De Monbrison & S. Picot

Authors
  1. M. Michallet
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. Bénet
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Sobh
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. Kraghel
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. El Hamri
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G. Cannas
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. F. E. Nicolini
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. H. Labussière
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. S. Ducastelle
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. F. Barraco
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. X. Thomas
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Y. Chelghoum
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. M.-C. Nicolle
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. A.-L. Bienvenu
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. F. Persat
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. F. De Monbrison
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. S. Picot
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. P. Vanhems
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Michallet.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Michallet, M., Bénet, T., Sobh, M. et al. Invasive aspergillosis: an important risk factor on the short- and long-term survival of acute myeloid leukemia (AML) patients. Eur J Clin Microbiol Infect Dis 31, 991–997 (2012). https://doi.org/10.1007/s10096-011-1397-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10096-011-1397-5

Keywords

Search

Navigation